Related references
Note: Only part of the references are listed.Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Natural Expression of the CD19 Antigen Impacts the Long-Term Engraftment but Not Antitumor Activity of CD19-Specific Engineered T Cells
Eleanor J. Cheadle et al.
JOURNAL OF IMMUNOLOGY (2010)
Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice
Scott E. James et al.
BLOOD (2009)
The promise and potential pitfalls of chimeric antigen receptors
Michel Sadelain et al.
CURRENT OPINION IN IMMUNOLOGY (2009)
A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity
Yangbing Zhao et al.
JOURNAL OF IMMUNOLOGY (2009)
Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
James N. Kochenderfer et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone et al.
MOLECULAR THERAPY (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Genetically engineered T cells expressing a HER2-specific chimeric receptor mediate antigen-specific tumor regression
S. Li et al.
CANCER GENE THERAPY (2008)
Redirecting specificity of T-cell Populations for CD19 using the Sleeping beauty system
Harjeet Singh et al.
CANCER RESEARCH (2008)
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
Mark E. Dudley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo
Cor H. J. Lamers et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Induction of tolerance in CD8+ T cells to a transgenic autoantigen expressed in the liver does not require cross-presentation
Junko Morimoto et al.
JOURNAL OF IMMUNOLOGY (2007)
Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses
James N. Kochenderfer et al.
JOURNAL OF IMMUNOLOGY (2006)
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells
Claudia M. Kowolik et al.
CANCER RESEARCH (2006)
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer
Michael H. Kershaw et al.
CLINICAL CANCER RESEARCH (2006)
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells
A. Loskog et al.
LEUKEMIA (2006)
Rapid specific amplification of rat antibody cDNA from nine hybridomas in the presence of myeloma light chains
Jamie L. Brady et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2006)
Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors
C Rossig et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Supernatural T cells: Genetic modification of T cells for cancer therapy
MH Kershaw et al.
NATURE REVIEWS IMMUNOLOGY (2005)
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells
L Gattinoni et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions
MS Hughes et al.
HUMAN GENE THERAPY (2005)
CD8+T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells
PA Antony et al.
JOURNAL OF IMMUNOLOGY (2005)
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy
CA Klebanoff et al.
TRENDS IN IMMUNOLOGY (2005)
Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes
JH Pinthus et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Naturally arising CD4(+) regulatory T cells for immunologic self-tolerance and negative control of immune responses
S Sakaguchi
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Identification of a murine CD28 dileucine motif that suppresses single-chain chimeric T-cell receptor expression and function
P Nguyen et al.
BLOOD (2003)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
RJ Brentjens et al.
NATURE MEDICINE (2003)
Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen
AD Higgins et al.
JOURNAL OF IMMUNOLOGY (2002)
Redirecting mouse CTL against colon carcinoma: Superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma
NM Haynes et al.
JOURNAL OF IMMUNOLOGY (2001)
Share Paper
